<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371173</url>
  </required_header>
  <id_info>
    <org_study_id>ORION-PH-1</org_study_id>
    <nct_id>NCT03371173</nct_id>
  </id_info>
  <brief_title>ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1)</brief_title>
  <acronym>ORION-PH-1</acronym>
  <official_title>A Pilot Study to Explore Preliminary Safety, Tolerability and Efficacy of ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency in Patients With Pulmonary Hypertension and Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shields, Shields and Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an explorative, open-label, uncontrolled, single center study to explore the
      preliminary safety, tolerability and efficacy of oral ferric maltol in treating iron
      deficiency in patients with pulmonary hypertension and iron deficiency anemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Explorative, open-label, uncontrolled monocenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin level from baseline to week 12</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>measurement of hemoglobin in blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin from baseline to week 6</measure>
    <time_frame>baseline to week 6</time_frame>
    <description>measurement of hemoglobin in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum ferritin levels from baseline to week 6 and 12</measure>
    <time_frame>baseline to week 6 and baseline to week 12</time_frame>
    <description>measurement of serum ferritin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transferrin saturation from baseline to week 6 and 12</measure>
    <time_frame>baseline to week 6 and baseline to week 12</time_frame>
    <description>measurement of transferrin saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 min walking distance from baseline to week 12</measure>
    <time_frame>baseline to week 12</time_frame>
    <description>measurement of functional exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum NT-proBNP from baseline to weeks 6 and 12</measure>
    <time_frame>baseline to week 6 and baseline to week 12</time_frame>
    <description>measurement of serum NT-proBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic markers of right ventricular function from baseline to week 12 (1)</measure>
    <time_frame>from baseline to week 12</time_frame>
    <description>measurement of right atrial area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic markers of right ventricular function from baseline to week 12 (2)</measure>
    <time_frame>from baseline to week 12</time_frame>
    <description>measurement of right ventricular diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic markers of right ventricular function from baseline to week 12 (3)</measure>
    <time_frame>from baseline to week 12</time_frame>
    <description>measurement of fractional area change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiographic markers of right ventricular function from baseline to week 12 (4)</measure>
    <time_frame>from baseline to week 12</time_frame>
    <description>measurement of tricuspid annular plane systolic excursion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in World Health Organization Functional Class (WHO FC) from baseline to week 6 and week 12</measure>
    <time_frame>from baseline to week 6 and week 12</time_frame>
    <description>measurement of different parameter according to an evaluated process</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events [Safety and Tolerability]</measure>
    <time_frame>first application of IMP until 4 weeks after treatment discontinuation</time_frame>
    <description>Number of Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Serious Adverse Events [Safety and Tolerability]</measure>
    <time_frame>first application of IMP until 4 weeks after treatment discontinuation</time_frame>
    <description>Number of Serious Adverse Events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Anemia, Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Ferric maltol 30 mg (Feraccru®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric maltol 30 mg (Feraccru®)</intervention_name>
    <description>Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects</description>
    <arm_group_label>Ferric maltol 30 mg (Feraccru®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent prior to any study-related procedure and willingness
             to comply with treatment and follow-up procedures

          2. Male and female patients ≥18 years at day of inclusion

          3. Patients capable of understanding the investigational nature, potential risks and
             benefits of the clinical trial

          4. Patients with a diagnosis of PH confirmed by a (historical) right heart
             catheterization showing a mean pulmonary artery pressure ≥25 mmHg at rest and stable
             PH medication for at least 3 months.

          5. 6 min walk distance &gt;50 m

          6. Mild-to-moderate iron-deficiency anemia as defined by a hemoglobin concentration ≥7
             g/dl and &lt;12 g/dl in females or ≥8 g/dl and &lt;13 g/dl in males, and serum ferritin &lt;100
             µg/l, or 100-300 µg/l and transferrin saturation &lt;20% at screening

          7. Prevention of pregnancy:

        Women without childbearing potential defined as follows:

          -  at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral
             oophorectomy or

          -  hysterectomy or uterine agenesis or

          -  ≥ 50 years and in postmenopausal state ≥ 1 year or

          -  &lt; 50 years and in postmenopausal state ≥ 1 year with serum FSH &gt; 40 IU/l and serum
             oestrogen &lt; 30 ng/l or a negative oestrogen test or

        Women of childbearing potential with a negative ß-HCG pregnancy test at screening who agree
        to meet one of the following criteria from the time of screening, during the study and for
        a period of four weeks following the last administration of study medication:

          -  correct use of contraception methods. The following are acceptable: hormonal
             contraceptives (combined oral contraceptives and oestrogen-free pills with
             desogestrel, implants, transdermal patches, hormonal vaginal devices or injections
             with prolonged release), intrauterine device (IUS) or a barrier method, e.g. condom or
             occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film,
             cream or suppository)

          -  true abstinence (periodic abstinence and withdrawal are not acceptable methods of
             contraception)

          -  sexual relationship only with female partners and/or sterile male partners

        Exclusion Criteria:

          1. Active hematological disorders other than iron-deficiency anemia

          2. Other medical condition that according to the investigator's assessment is causing or
             contributing to anemia

          3. Active malignancy

          4. Active infectious disease

          5. Active bleeding

          6. Severe renal insufficiency (glomerular filtration rate &lt;30 ml/min)

          7. Severe liver injury as indicated by serum aminotransferases &gt;3 x upper limit of normal
             or bilirubin levels &gt;50 µmol/l

          8. Ongoing oral or intravenous iron supplementation

          9. Hemoglobin &lt;7 g/dl in females or &lt;8 g/dl in males at screening

         10. Concomitant erythropoietin medication

         11. Pregnancy or lactation period

         12. Subject has received any investigational medication or any investigational device
             within 30 days prior to the first dose of study medication or is actively
             participating in any investigational drug/devices trial, or is scheduled to receive an
             investigational drug/device during the course of the study.

         13. Known or suspected hypersensitivity to any of the active substances or any excipients
             of the investigational medicinal product

         14. Known haemochromatosis or other iron overload syndromes

         15. Patients who have been receiving repeated (&gt;1) blood transfusions during the past 6
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marius Hoeper, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School, Department of Pneumology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marius Hoeper, Prof. Dr.</last_name>
    <phone>+49 511-532</phone>
    <phone_ext>3530</phone_ext>
    <email>hoeper.marius@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marius M Hoeper, MD</last_name>
      <phone>0049 511 532 3530</phone>
      <email>hoeper.marius@mh-hannover.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Iron Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

